EA202190907A1 - Репликоны на основе альфавируса для введения биотерапевтических средств - Google Patents
Репликоны на основе альфавируса для введения биотерапевтических средствInfo
- Publication number
- EA202190907A1 EA202190907A1 EA202190907A EA202190907A EA202190907A1 EA 202190907 A1 EA202190907 A1 EA 202190907A1 EA 202190907 A EA202190907 A EA 202190907A EA 202190907 A EA202190907 A EA 202190907A EA 202190907 A1 EA202190907 A1 EA 202190907A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- alphavirus
- nsp3
- hypervariable domain
- domain
- world alphavirus
- Prior art date
Links
- 241000710929 Alphavirus Species 0.000 title abstract 4
- 241000124008 Mammalia Species 0.000 abstract 2
- 101800000515 Non-structural protein 3 Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 108700004885 alphavirus nsp3 Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 102000001008 Macro domains Human genes 0.000 abstract 1
- 108050007982 Macro domains Proteins 0.000 abstract 1
- 101800000980 Protease nsP2 Proteins 0.000 abstract 1
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 abstract 1
- 101710172711 Structural protein Proteins 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862742868P | 2018-10-08 | 2018-10-08 | |
| PCT/US2019/055125 WO2020076775A1 (en) | 2018-10-08 | 2019-10-08 | Alphavirus-based replicons for administration of biotherapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190907A1 true EA202190907A1 (ru) | 2021-06-25 |
Family
ID=68343515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190907A EA202190907A1 (ru) | 2018-10-08 | 2019-10-08 | Репликоны на основе альфавируса для введения биотерапевтических средств |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12331076B2 (https=) |
| EP (1) | EP3864027A1 (https=) |
| JP (2) | JP7846986B2 (https=) |
| KR (1) | KR20210074314A (https=) |
| CN (1) | CN113227122B (https=) |
| AU (1) | AU2019359204B2 (https=) |
| BR (1) | BR112021006614A2 (https=) |
| CA (1) | CA3115480A1 (https=) |
| CL (1) | CL2021000855A1 (https=) |
| CO (1) | CO2021006453A2 (https=) |
| EA (1) | EA202190907A1 (https=) |
| IL (1) | IL282043A (https=) |
| MA (1) | MA53858A (https=) |
| MX (1) | MX2021004032A (https=) |
| PH (1) | PH12021550759A1 (https=) |
| SG (1) | SG11202103167VA (https=) |
| WO (1) | WO2020076775A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US20220313815A1 (en) * | 2019-06-20 | 2022-10-06 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| JP2023524055A (ja) * | 2020-04-30 | 2023-06-08 | ブイエルピー・セラピューティクス・インコーポレイテッド | サイトカイン免疫療法 |
| AU2021271300A1 (en) | 2020-05-11 | 2023-02-02 | Janssen Pharmaceuticals, Inc. | RNA replicon encoding a stabilized corona virus spike protein |
| EP4367253A4 (en) * | 2021-07-09 | 2025-06-04 | Replicate Bioscience, Inc. | Modified eastern equine encephalitis viruses, self-replicating rna constructs, and uses thereof |
| TW202313967A (zh) * | 2021-07-30 | 2023-04-01 | 美商亞克圖羅斯醫療公司 | Ｒｎａ疫苗 |
| CN113846113B (zh) * | 2021-09-09 | 2022-09-13 | 臻赫医药(杭州)有限公司 | 一种有限自我复制mRNA分子系统、制备方法及应用 |
| US11510975B1 (en) * | 2021-11-29 | 2022-11-29 | Replicate Bioscience, Inc. | Compositions and methods for inducing ESR1, PI3K, HER2, and HER3 immune responses |
| CN114317563B (zh) * | 2021-12-17 | 2023-09-05 | 华南理工大学 | 提高基因表达的rna复制子及其应用 |
| WO2023205644A1 (en) * | 2022-04-19 | 2023-10-26 | Replicate Bioscience, Inc. | Modified western equine encephalitis viruses and uses thereof |
| CN116179603B (zh) * | 2022-09-30 | 2024-10-29 | 中国科学院深圳先进技术研究院 | 稳定表达外源基因的sinv载体及其制备方法和应用 |
| WO2025017036A1 (en) * | 2023-07-17 | 2025-01-23 | Institut National de la Santé et de la Recherche Médicale | Alphavirus nsp3 helical tubular scaffolds |
| WO2025016031A1 (zh) * | 2023-07-19 | 2025-01-23 | 上海复诺健生物科技有限公司 | 自扩增核酸分子及其应用 |
| CN118147171B (zh) * | 2024-03-08 | 2024-12-06 | 上海复诺健生物科技有限公司 | 具有增强的外源基因表达水平的自扩增mRNA核酸序列 |
| WO2025104023A1 (en) | 2023-11-13 | 2025-05-22 | Ziphius Nv | MODIFIED ALPHAVIRAL nsP3 |
| CN118086395B (zh) * | 2024-04-25 | 2024-06-21 | 南京农业大学三亚研究院 | 一种盖塔病毒质粒载体、弱毒株及其制备方法和应用 |
| CN119639774A (zh) * | 2024-12-13 | 2025-03-18 | 北京剂泰医药科技有限公司 | 自复制rna分子组合及其应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| DE3377363D1 (en) | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| US4966843A (en) | 1982-11-01 | 1990-10-30 | Cetus Corporation | Expression of interferon genes in Chinese hamster ovary cells |
| US4892743A (en) | 1983-12-21 | 1990-01-09 | Schering Corporation | Novel hybrid interferon species |
| EP0165942A1 (en) | 1983-12-23 | 1986-01-02 | Monash University | PRODUCTION OF HUMAN INTERFERON-$g(a) |
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| WO1990006370A1 (en) | 1988-12-01 | 1990-06-14 | The Trustees Of The University Of North Carolina | Synthetic interleukin-6 |
| US5225337A (en) | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Ribozyme compositions and methods for use |
| US5246921A (en) | 1990-06-26 | 1993-09-21 | The Wistar Institute Of Anatomy And Biology | Method for treating leukemias |
| US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| DK0726758T3 (da) | 1993-08-02 | 2003-03-03 | Scripps Research Inst | Peptider til inducering af cytotoksiske T-lymfocytreaktioner over for hepaptitis B virus |
| SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US6041252A (en) | 1995-06-07 | 2000-03-21 | Ichor Medical Systems Inc. | Drug delivery system and method |
| DE19712889A1 (de) | 1997-03-27 | 1998-10-01 | Bosch Gmbh Robert | Verfahren und Vorrichtung zur Ermittlung einer den Systemdruck in einem Bremskreis beschreibenden Größe |
| JP2001520537A (ja) | 1997-04-03 | 2001-10-30 | エレクトロフェクト・アクティーゼルスカブ | 医薬品と核酸の骨格筋への導入方法 |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| US5873849A (en) | 1997-04-24 | 1999-02-23 | Ichor Medical Systems, Inc. | Electrodes and electrode arrays for generating electroporation inducing electrical fields |
| GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
| US6117660A (en) | 1997-06-10 | 2000-09-12 | Cytopulse Sciences, Inc. | Method and apparatus for treating materials with electrical fields having varying orientations |
| HUP0004589A3 (en) | 1997-06-30 | 2003-08-28 | Centre Nat Rech Scient | Improved method for transferring nucleic acid into the striped muscle and combination therefor |
| US5958060A (en) | 1998-01-02 | 1999-09-28 | General Electric Company | Method and apparatus for clock control and synchronization |
| EP1100579B1 (en) | 1998-07-13 | 2015-09-02 | Inovio Pharmaceuticals, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US6319901B1 (en) | 1998-10-15 | 2001-11-20 | Ichor Medical Systems, Inc. | Methods for prolonging cell membrane permeability |
| US20040213805A1 (en) | 1999-10-12 | 2004-10-28 | Verheije Monique Helene | Deletions in arterivirus replicons |
| US6982087B2 (en) | 2000-09-07 | 2006-01-03 | The University Of North Carolina At Chapel Hill | Vectors derived from South African Arbovirus No. 86 |
| US6538922B1 (en) | 2000-09-27 | 2003-03-25 | Sandisk Corporation | Writable tracking cells |
| PL212047B1 (pl) | 2000-11-23 | 2012-08-31 | Bavarian Nordic As | Zmodyfikowany wirus krowianki szczepu Ankara MVA-BN i jego pochodna, genom i zawierające je kompozycja farmaceutyczna, zwłaszcza szczepionka oraz ich zastosowania |
| AU2002242016A1 (en) | 2001-02-01 | 2002-08-12 | The Johns Hopkins University | Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation |
| AU2002303330B2 (en) | 2001-05-31 | 2008-07-24 | Novartis Vaccines And Diagnostics, Inc. | Chimeric alphavirus replicon particles |
| EP1278382B1 (en) | 2001-07-19 | 2007-02-14 | Telefonaktiebolaget LM Ericsson (publ) | Method and apparatus for solving number portability in origin |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US6912417B1 (en) | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| US6943015B2 (en) | 2002-12-12 | 2005-09-13 | Ilya Frolov | Large scale production of packaged alphavirus replicons |
| US8080255B2 (en) | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| DE602004021260D1 (de) | 2003-07-11 | 2009-07-09 | Alphavax Inc | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
| US20050070700A1 (en) | 2003-09-30 | 2005-03-31 | Matthias Giese | Equine arteritis virus vaccine |
| CA2559083C (en) | 2004-03-08 | 2015-06-16 | Ichor Medical Systems, Inc. | Improved apparatus for electrically mediated delivery of therapeutic agents |
| EP1751289B1 (en) | 2004-05-18 | 2009-01-14 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
| US20090104226A1 (en) | 2004-05-21 | 2009-04-23 | Novartis Vaccines And Diagnostics Inc. | Alphavirus Vectors for Respiratory Pathogen Vaccines |
| CA2572921C (en) | 2004-07-09 | 2017-01-03 | The University Of North Carolina At Chapel Hill | Replication-competent and propagation-defective venezuelan equine encephalitis (vee) viral adjuvants |
| CN101548014B (zh) | 2006-06-06 | 2012-07-04 | 墨尔本保健公司 | 抗病毒抗性突变的检测和应用 |
| EP2062246A4 (en) | 2006-08-18 | 2010-09-29 | Univ North Carolina | VACCINES AGAINST CHIMARICAL VIRUSES |
| ES2993941T3 (en) | 2006-10-17 | 2025-01-14 | Inovio Pharmaceuticals Inc | Electroporation devices for electroporation of cells in mammals |
| US20090018031A1 (en) | 2006-12-07 | 2009-01-15 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways tools, and methods |
| KR100836745B1 (ko) | 2007-01-31 | 2008-06-10 | (주)두비엘 | Ｈｂｖ 백신 및 그의 제조 방법 |
| DK2947149T3 (en) | 2007-06-21 | 2018-06-06 | Alphavax Inc | ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION |
| US20110110974A1 (en) | 2007-10-29 | 2011-05-12 | Erik Depla | Methods and kits for inducing a ctl response using a prime boost regimen |
| TWI555531B (zh) | 2009-08-07 | 2016-11-01 | 傳斯堅公司 | 用以治療ｂ型肝炎病毒（ｈｂｖ）感染之組成物 |
| EP2519266B1 (en) | 2009-12-31 | 2017-07-26 | Medigen, Inc. | Infectious dna vaccines against chikungunya virus |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| DK2655621T3 (en) | 2010-12-20 | 2018-08-13 | Massachusetts Gen Hospital | Polycomb-associated non-coding RNAS |
| CN103442732B (zh) | 2011-02-11 | 2017-04-12 | 宾夕法尼亚大学托管会 | 编码乙型肝炎病毒核心蛋白的核酸分子和包含其的疫苗 |
| KR102081868B1 (ko) | 2011-06-28 | 2020-02-26 | 이노비오 파마수티컬즈, 인크. | 최소 침습 피부 전기천공 장치 |
| TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| CN104508131B (zh) * | 2012-05-21 | 2018-11-23 | 加利福尼亚大学董事会 | 通过合成的自我复制的RNA形成人iPS细胞 |
| US8961995B2 (en) | 2012-09-20 | 2015-02-24 | Uab Research Foundation | Methods and compositions for alphavirus replicons |
| EP2932993B1 (en) | 2012-12-13 | 2017-03-29 | Panasonic Healthcare Holdings Co., Ltd. | Medicament injection device |
| WO2014170493A2 (en) | 2013-04-19 | 2014-10-23 | Novartis Ag | Alphavirus vector |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| WO2016020538A1 (en) | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| AU2015323944B2 (en) | 2014-10-01 | 2018-11-29 | Inovio Pharmaceuticals, Inc. | Vaccines having an antigen and interleukin-21 as an adjuvant |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| KR20180004820A (ko) | 2015-05-15 | 2018-01-12 | 큐어백 아게 | 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법 |
| EP4137150A1 (en) | 2015-08-03 | 2023-02-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
| EP3436139B1 (en) | 2016-03-28 | 2025-04-30 | PapiVax Biotech, Inc. | METHOD AND APPARATUS FOR ADMINISTERING THERAPEUTIC AGENTS |
| US11324819B2 (en) | 2016-04-06 | 2022-05-10 | University Of Washington | Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen |
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| KR102718353B1 (ko) | 2016-10-17 | 2024-10-15 | 얀센 파마슈티칼즈, 인코포레이티드 | 재조합 바이러스 레플리콘 시스템 및 그의 용도 |
| JP7788787B2 (ja) | 2016-12-05 | 2025-12-19 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | 遺伝子発現増強のための組成物および方法 |
| US11471527B2 (en) | 2017-06-05 | 2022-10-18 | Beacle Inc. | Virus-like particles including HBs-L antigen protein for causing immune response against HBV |
| CN117866990A (zh) | 2017-11-16 | 2024-04-12 | 华盛顿大学 | 使用HBV包膜蛋白的HBV PreS1和/或PreS2和/或S-HBsAg区域的治疗乙型肝炎病毒（HBV）的疫苗 |
| EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| ES2963179T3 (es) | 2017-12-19 | 2024-03-25 | Janssen Sciences Ireland Unlimited Co | Vacunas contra el virus de la hepatitis b (VHB) y usos de las mismas |
-
2019
- 2019-10-08 KR KR1020217013479A patent/KR20210074314A/ko active Pending
- 2019-10-08 MA MA053858A patent/MA53858A/fr unknown
- 2019-10-08 CA CA3115480A patent/CA3115480A1/en active Pending
- 2019-10-08 EA EA202190907A patent/EA202190907A1/ru unknown
- 2019-10-08 US US16/595,980 patent/US12331076B2/en active Active
- 2019-10-08 EP EP19794362.4A patent/EP3864027A1/en active Pending
- 2019-10-08 BR BR112021006614-4A patent/BR112021006614A2/pt unknown
- 2019-10-08 MX MX2021004032A patent/MX2021004032A/es unknown
- 2019-10-08 WO PCT/US2019/055125 patent/WO2020076775A1/en not_active Ceased
- 2019-10-08 SG SG11202103167VA patent/SG11202103167VA/en unknown
- 2019-10-08 JP JP2021518944A patent/JP7846986B2/ja active Active
- 2019-10-08 CN CN201980079187.XA patent/CN113227122B/zh active Active
- 2019-10-08 AU AU2019359204A patent/AU2019359204B2/en not_active Ceased
-
2021
- 2021-04-04 IL IL282043A patent/IL282043A/en unknown
- 2021-04-06 CL CL2021000855A patent/CL2021000855A1/es unknown
- 2021-04-06 PH PH12021550759A patent/PH12021550759A1/en unknown
- 2021-05-19 CO CONC2021/0006453A patent/CO2021006453A2/es unknown
-
2025
- 2025-07-11 JP JP2025117208A patent/JP2025160243A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020076775A1 (en) | 2020-04-16 |
| US20200109178A1 (en) | 2020-04-09 |
| MA53858A (fr) | 2021-09-15 |
| JP7846986B2 (ja) | 2026-04-16 |
| IL282043A (en) | 2021-05-31 |
| EP3864027A1 (en) | 2021-08-18 |
| CL2021000855A1 (es) | 2021-11-26 |
| MX2021004032A (es) | 2021-07-06 |
| AU2019359204B2 (en) | 2024-12-05 |
| CA3115480A1 (en) | 2020-04-16 |
| JP2022512625A (ja) | 2022-02-07 |
| CO2021006453A2 (es) | 2021-05-31 |
| JP2025160243A (ja) | 2025-10-22 |
| CN113227122B (zh) | 2025-05-06 |
| CN113227122A (zh) | 2021-08-06 |
| SG11202103167VA (en) | 2021-04-29 |
| AU2019359204A1 (en) | 2021-04-29 |
| PH12021550759A1 (en) | 2021-12-13 |
| KR20210074314A (ko) | 2021-06-21 |
| BR112021006614A2 (pt) | 2021-07-20 |
| US12331076B2 (en) | 2025-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190907A1 (ru) | Репликоны на основе альфавируса для введения биотерапевтических средств | |
| US11826416B2 (en) | Induce and enhance immune responses using recombinant replicon systems | |
| UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
| PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
| MXPA05010007A (es) | Replicones de alfavirus y construcciones auxiliares mejorados. | |
| MX2020010466A (es) | Vectores de virus que evitan anticuerpos. | |
| EA201991911A1 (ru) | Способы и композиции для переноса генов по сосудистой сети | |
| MX2021015182A (es) | Casetes optimizados de expresion del gen humano del factor viii de coagulacion y su uso. | |
| MX2019004499A (es) | Sistemas de replicón de virus recombinante y usos de estos. | |
| MX2019000962A (es) | Novedosas proteinas de la capside del virus adenoasociado. | |
| MY208114A (en) | Hbv vaccines and methods treating hbv | |
| MX2018010850A (es) | Métodos para producir proteínas de fusión de toxina diftérica monoméricas y libres de agregados y usos terapéuticos. | |
| EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
| MX2020010464A (es) | Vectores de virus que evitan anticuerpos. | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| PE20200722A1 (es) | Metodos de terapia genica del factor viii (fviii) | |
| WO2014170493A3 (en) | Alphavirus vector | |
| MX2022014167A (es) | Replicón de arn que codifica una proteína de espícula del coronavirus estabilizada. | |
| ZA201707985B (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
| MX394834B (es) | Proteína de fusión para usarse en el tratamiento/prevención de una infección por virus de hepatitis b. | |
| MX2023003934A (es) | Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos. | |
| PH12018502197A1 (en) | Improved method for producing virus like particles | |
| EP4265631A3 (en) | Live-attenuated flaviruses with heterologous antigens | |
| EA201990719A1 (ru) | Новые промоторы | |
| EA202092065A1 (ru) | ЭКСПРЕССИЯ ПНЕВМОКОККОВОГО ПОВЕРХНОСТНОГО БЕЛКА А (PspA) |